Low long-term risk of breast cancer recurrence after nipple-sparing mastectomy

byWolters Kluwer HealthCredit: Pixabay/CC0 Public DomainNipple-sparing mastectomy (NSM)—an increasingly popular option for women undergoing treatment for breast cancer—not only achieves good cos

Updated on: December 19,2023

Low long-term risk of breast cancer recurrence after nipple-sparing mastectomy

byWolters Kluwer HealthCredit: Pixabay/CC0 Public DomainNipple-sparing mastectomy (NSM)—an increasingly popular option for women undergoing treatment for breast cancer—not only achieves good cos

Updated on:December 19,2023

PSMA PET scanning can improve decision making for prostate cancer treatment

bySociety of Nuclear MedicineHeat map of prostate bed PSMA PET recurrences distribution in the miTr N0 Mo cohort (n=127 patients) mapped on a template patient’s anatomy (the green contour repres

Updated on: December 17,2023

PSMA PET scanning can improve decision making for prostate cancer treatment

bySociety of Nuclear MedicineHeat map of prostate bed PSMA PET recurrences distribution in the miTr N0 Mo cohort (n=127 patients) mapped on a template patient’s anatomy (the green contour repres

Updated on:December 17,2023

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances i

Updated on: November 21,2023

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances i

Updated on:November 21,2023

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on: October 24,2023

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on:October 24,2023

Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer

by Impact JournalsExpression of lncRNA MVIH in CC tumor as compared to marginal non-tumor tissues. Credit:Genes & Cancer(2022). DOI: 10.18632/genesandcancer.224A new research paper was

Updated on: December 17,2023

Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer

by Impact JournalsExpression of lncRNA MVIH in CC tumor as compared to marginal non-tumor tissues. Credit:Genes & Cancer(2022). DOI: 10.18632/genesandcancer.224A new research paper was

Updated on:December 17,2023

3-Week Course of Radiotherapy May Offer Greater Convenience for Patients With Soft Tissue Sarcoma

December 29, 2022Jason HarrisModerately hypofractionated preoperative radiotherapy did not increase risk for major wound complication in patients with soft tissue sarcomas, according to findings from

Updated on: October 17,2023

3-Week Course of Radiotherapy May Offer Greater Convenience for Patients With Soft Tissue Sarcoma

December 29, 2022Jason HarrisModerately hypofractionated preoperative radiotherapy did not increase risk for major wound complication in patients with soft tissue sarcomas, according to findings from

Updated on:October 17,2023

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on: October 17,2023

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on:October 17,2023

Study finds less-aggressive chemotherapy after initial treatment for metastatic colorectal cancer to be more beneficial

byMayo ClinicCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenanc

Updated on: December 22,2023

Study finds less-aggressive chemotherapy after initial treatment for metastatic colorectal cancer to be more beneficial

byMayo ClinicCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenanc

Updated on:December 22,2023

Saliva test shows promise for earlier and easier detection of mouth and throat cancer

byElsevierAcoustofluidic exosome isolation chip for salivary exosome isolation. The microfluidic channel is shown by red dye solution and the coin demonstrates the size of the chip. Two pairs of

Updated on: December 22,2023

Saliva test shows promise for earlier and easier detection of mouth and throat cancer

byElsevierAcoustofluidic exosome isolation chip for salivary exosome isolation. The microfluidic channel is shown by red dye solution and the coin demonstrates the size of the chip. Two pairs of

Updated on:December 22,2023

Study identifies skin microbiome as a factor in stem cell transplants

Study identifies skin microbiome as a factor in stem cell transplantsbyMedical University of ViennaCredit: AI-generated imageOrgan damage occurs in up to 70% of patients in the first few months

Updated on: October 30,2023

Study identifies skin microbiome as a factor in stem cell transplants

Study identifies skin microbiome as a factor in stem cell transplantsbyMedical University of ViennaCredit: AI-generated imageOrgan damage occurs in up to 70% of patients in the first few months

Updated on:October 30,2023

AI's Breakthroughs in Ovarian Cancer Diagnosis and Treatment

Updated on: June 12,2024

AI's Breakthroughs in Ovarian Cancer Diagnosis and Treatment

Updated on:June 12,2024

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on: December 22,2023

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on:December 22,2023